

Searching the Linkage between High Fat Diet and Alzheimer's Disease: A Debatable Proof Stand for Ketogenic Diet to Alleviate Symptoms of Alzheimer's Patient with APOE ϵ 4 Allele

Md. Sahab Uddin^{1*}, Anamul Haque², Abdullah Al Mamun¹, Mohammed Ashrafal Iqbal³, Md. Tanvir Kabir⁴, Ram Kamol Rony⁵ and Mst. Marium Begum⁶

¹Department of Pharmacy, Southeast University, Dhaka, Bangladesh

²Department of Pharmacy, Comilla University, Comilla, Bangladesh

³Department of Chemistry, Fareast International University, Dhaka, Bangladesh

⁴Department of Pharmacy, BRAC University, Dhaka, Bangladesh

⁵Department of Pharmacology and Clinical Pharmacy, North South University, Dhaka, Bangladesh

⁶Department of Pharmacy, East West University, Dhaka, Bangladesh

*Corresponding author: Md. Sahab Uddin, Department of Pharmacy, Southeast University, Dhaka, Bangladesh, Tel: +8801710220110; +8801670760546; E-mail: msu_neuropharma@hotmail.com; msu_neuropharma@hotmail.com

Received date: July 22, 2016; Accepted date: October 19, 2016; Published date: October 26, 2016

Copyright: © 2016 Uddin MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Alzheimer's disease (AD) is an incurable neurodegenerative form of dementia affecting millions of individuals worldwide. A hallmark of AD is the deregulation of the level of β -amyloid ($A\beta$) that leads to the appearance of the senile plaques that contain $A\beta$ derived from the cleavage of the amyloid precursor protein. Among numerous risk factors for AD, genetic risk factor such as possession of ϵ 4 allele of apolipoprotein E (ApoE4) is considered as a crucial risk factor. Moreover, dietary fat composition has also been concerned as an important factor for AD since cholesterol and blood-brain barrier functions are linked with AD. The primary genetic risk factor is ApoE ϵ 4 allele that encodes one of several proteins responsible for cholesterol transport and it is considered as foremost cholesterol transport proteins in the brain. For the progression of AD high level of serum/plasma cholesterol has been recommended as a causative factor. But this statement is debatable meanwhile brain cholesterol levels of AD patients are highly variable and cholesterol levels in serum/plasma and brain of AD patients do not consider cholesterol as a risk factor in AD. Indeed, APOE ϵ 4 is neither essential nor enough for the development of AD, it only serves as a synergistic and increases the risk of AD. Another prominent feature of AD is region-specific declines in brain glucose metabolism. The brain cells are totally different from other cells of the body, the brain cells cannot competently metabolize fats, therefore completely depends on glucose as an energy substrate. Consequently, inhibition of glucose metabolism can have intense effects on the brain functions. As a result hypo-metabolism observed in AD has just attained considerable attention as a probable target for interference in the disease progression. One propitious way is to maintain the regular glucose supply to the brain with ketone bodies from ketogenic diet represents a potent therapeutic for AD. Therefore the objective of this study was to analyze the relationship of the high dietary fat composition to the risk of developing AD by considering the impact of ApoE genotype.

Keywords: Alzheimer's disease; Amyloid- β ; High fat diet; Ketogenic diet; Ketone bodies; APOE ϵ 4

Abbreviations AD: Alzheimer's Disease; $A\beta$: β -Amyloid; APP: Amyloid Precursor Protein; BACE1: β -site APP-Cleaving Enzyme 1; PSEN1: Presenilin 1; PSEN2: Presenilin 2; APOE: Apolipoprotein E; AHRQ: Agency for Healthcare Research and Quality; KD: Ketogenic Diets; BBB: Blood-Brain Barrier; CSF: Cerebrospinal Fluid; CNS: Central Nervous System; LDL: Low Density Lipoprotein; SFA: Saturated Fatty Acids; TFA: Trans Fatty Acids, MUFA: Monounsaturated Fatty Acids; PUFA: Polyunsaturated Fatty Acids; GC: Global Cognitive; MCI: Mild Cognitive Impairment; MMSE: Mini Mental State Examination; VD: Vascular Dementia; ATP: Adenosine Triphosphate; β -OHB: β -Hydroxybutyrate; MCTG: Medium Chain Triglycerides; ϵ 4+: Subjects with Apo ϵ 4; ϵ 4-: Subjects without Apo ϵ 4; ADAS-cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-CGIC: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change; ITT: Intention-To-Treat;

PP: Per Protocol; DC: Dosage Compliant; CDR: Clinical Dementia Rating, TMT: Trail Making Test; V-PAL: Verbal Paired Associate Learning; GDS: Geriatric Depression Scale; CO: Coconut Oil; MCFA: Medium-Chain Fatty Acids; MCT: Medium-Chain Triglyceride; ADLs: Activities of Daily Living; MRI: Magnetic Resonance Imaging; KME: Ketone Monoester

Introduction

Alzheimer's disease (AD) is an irreversible, neurodegenerative disorders and the most common cause of dementia account for 60 to 70% of cases, mostly affecting people older than 65 years of age [1]. Worldwide AD affects approximately 35.6 million people. This will increase with aging owing to the baby boomers generation becoming older and will probably affect nearly 106.8 million people by 2050 [2,3]. This progressive brain disorder is characterized by accumulation of extracellular senile plaques, dystrophic neurites and intracellular

neurofibrillar tangles [4,5]. The plaques mainly consist of the β -amyloid ($A\beta$) peptide which is derived from the cleavage of the amyloid precursor protein (APP) [6]. APP is a transmembrane protein that is vital for the growth, survival and repair of post-injury of neuron [7,8]. Proteolysis of APP is occurred by α -, β - and γ -secretases [9]. In the brain, β -secretase such as β -site APP-cleaving enzyme 1 (BACE1) is the major enzyme responsible for cleavage of APP to form C99 fragment and soluble APP β [10]. This generated C99 is cleaved by γ -secretase to produce several isoforms of neurotoxic $A\beta$ [11-13]. The most common isoforms are $A\beta$ 40 and $A\beta$ 42. Among these, two isoforms $A\beta$ 40 form is common and $A\beta$ 42 is the more fibrillogenic consequently linked to disease states [14].

Moreover, both presenilin 1 (PSEN1) and 2 (PSEN2) control the proteolytic function of γ -secretase and mutations in these proteins can change the activity of γ -secretase and increase the ratio of $A\beta$ in early-onset forms of AD [15]. $A\beta$ is a complex peptide of 36–43 amino acids which combines with various types of receptors and or generates insoluble agglomeration and eventually non-physiological aggregation of $A\beta$ alternate with the normal neuronal functions [16]. Although the exact role of $A\beta$ in the etiology of AD remains unclear, it is clear that $A\beta$ is a key risk factor and has a central role in the onset and progression of AD [17].

Early-onset and late-onset both forms of AD have a genetic component [18]. Early-onset AD occurs in people age 30 to 60 years and represents less than 5% of all people with Alzheimer's [19]. A number of different single-gene mutations on chromosomes 21, 14 and 1 are responsible for early-onset AD by the formation of abnormal proteins [20]. Mutations on chromosome 21 are responsible for the formation of abnormal APP [21]. A mutation on chromosome 14 causes the formation of abnormal PSEN1 as well as mutation on chromosome 1 leads to the formation of abnormal PSEN2 [22]. Aforementioned mutations play a vital role in the breakdown of APP. In fact, most of the Alzheimer's patients have the late-onset form and symptoms appear in the mid-60s and later [23]. The influence of a specific gene in late-onset AD is not yet completely understood. However, one genetic risk factor, i.e., having one form of the apolipoprotein E (APOE) gene on chromosome 19, does increase a person's risk [24]. There are various forms of APOE (i.e., ϵ 2, ϵ 3 and ϵ 4). APOE ϵ 2 is relatively rare and may provide little protective action against the disease. Generally, if AD occurs in a person with this allele, it develops later in life than it would in someone with the APOE ϵ 4 gene. APOE ϵ 3 is the most common allele that plays a neutral role in the Alzheimer's [25-27]. On the other hand APOE ϵ 4 is responsible for increasing the risk for AD and is also related to an earlier age of disease onset. A person has zero, one or two APOE ϵ 4 alleles. Having more APOE ϵ 4 alleles increases the risk of developing Alzheimer's, that's why APOE ϵ 4 is called a risk-factor gene. Several studies stated that between 40 and 80% of people with AD hold at least one APOE ϵ 4 allele [28]. The APOE ϵ 4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes [29]. However, inheriting an APOE ϵ 4 allele does not mean that a person will absolutely develop Alzheimer's. Some people with an APOE ϵ 4 allele never get the disease and others who develop Alzheimer's do not have any APOE ϵ 4 alleles [30,31].

Dietary factors are integrally linked with the development and propagation of AD [32]. A number of laboratory research and epidemiological studies have explored the associations between high fat diets and AD [33]. Using transgenic mouse models of AD, researchers have reported that high fat diets or diets with added

cholesterol increased the levels and deposition of the $A\beta$ peptide [34-38]. A number of studies suggested that high intake of saturated fats and trans fats is associated with the risk of AD [39-41]. In addition, few studies suggested that diets rich in omega-3 fatty acids may reduce the risk of AD. In addition, the Mediterranean diet is also associated with the reduced Alzheimer's risk [42]. Some have suggested that the regular consumption of fatty fish intake (i.e., more than twice per week) may be associated with lower risk for AD in individuals without the APOE ϵ 4 allele [43]. However, a systematic review by the Agency for Healthcare Research and Quality (AHRQ) concluded that data are inadequate to justify conclusions. Elevated cholesterol levels are associated with increased risk for AD, even after controlling for the presence of the APOE ϵ 4 allele [44].

The brain's principal energy substrate is glucose. Alzheimer's patients are unable to use glucose properly owing to lack of brain functions, but neurobiological evidence suggests that ketone bodies are an effective alternative energy substrate for the brain [45]. Diets that contain very low carbohydrate and high fat content are well known to induce the hepatic production of ketone bodies (i.e., β -hydroxybutyrate, acetoacetate and acetone) and are often referred to as ketogenic diets (KD) [46]. The neuroprotective effects of KD have been confirmed by several studies. Researchers confirmed that KDs can enhance cognitive function in pathophysiological as well as normal, healthy experimental animal systems [47,48]. Actually, most of the benefit of KB can be credited with their ability to increase mitochondrial efficiency and supplement the brain's normal reliance on glucose. Inquiry to examine the therapeutic potentiality of KB and ketosis represents a favorable new area of AD research [49,50].

The effect of high fat diet on AD is well known, but the relationship with ApoE is not well understood. Therefore the purpose of this study was to analyze the linkage between high fat diet and AD by envisaging ApoE.

Lipids in the pathophysiology of Alzheimer's disease

Lipids are vital for proper neuronal development associated with brain and brain functions [51]. The brain is the organ with highest lipid level that constitute 50–60% of the brain's dry weight and represents 25% of the total body cholesterol [52,53]. About 60–70% of the brain cholesterol are in myelin and another pool is neurons and glial cells [54]. Cholesterol is the functional component of all cell membranes, as well as structural support for the neural network. It is important in the formation and functioning of synapses, also serves as a brain antioxidant and an electrical insulator in order to avoid ion leakage [55].

In the development of AD, cholesterol may play a vital role [56]. Exactly, the core of the neuritic plaques that characterize AD is consisted of by cholesterol and neuritic plaques are thought that a crucial role of the APP is to clear excess cholesterol from the brain [56]. The most established genetic risk factor for AD is the ApoE ϵ 4 allele, which has been associated with nearly a doubling in the risk of developing AD [57]. ApoE ϵ 4 allele encodes one of several proteins involved in cholesterol transport and it is considered as chief cholesterol transport proteins in the brain. Several cohort studies also suggested that hypercholesterolemia increase the chance of developing dementia [58-61].

However, there are huge conflicts about the role of elevated cholesterol levels as a risk factor for AD. The study of Popp et al. suggested that plasma cholesterol levels were approximately 10%

higher in AD patients as compared to the control subjects and statistically significant [62]. But in another previous study of the same research team reported that plasma cholesterol levels of AD and control individuals were not statistically significant [63]. In another longitudinal study in case of the first exam, cholesterol levels were significantly higher in AD patients with respect to control subjects, but were not statistically significant at the second exam [64]. According to the study of the Whitmer et al. high cholesterol levels at mid-life were connected with the risk of developing late-life dementia. The outcome of this study recommended that out of 2844 subjects with cholesterol levels above 240 mg/dL only 266 were identified with dementia. A number of the Cox proportional hazards model, also suggested cholesterol levels as risk factors of developing AD [65]. But a previous meta-analysis of 10 studies published between 1986 and 1999 suggested opposite consequence [66]. This study endorsed that the cholesterol level of the AD patients was significantly lower than normal subjects [66]. In addition, Honolulu-Asia aging and Framingham studies found that serum cholesterol levels at mid-life were not associated with late-life dementia or AD [67]. Statistics suggest that in the USA, 98.9 million people have cholesterol levels of 200 mg/dL and higher and 31.9 million have cholesterol levels of 240 mg/dL and higher but only 4.7 million people have AD [68,69].

Another matter is that serum and plasma cholesterol levels are not in equilibrium with the brain cholesterol levels [70]. Usually, alteration of serum and plasma cholesterol does not affect brain cholesterol homeostasis [70]. The study of Kirsch et al. also suggested similar concern [71]. In fact, Erickson and Banks proposed that blood-brain barrier (BBB) may be dysfunctional in AD that could alter brain cholesterol homeostasis [70]. However, analysis of different brain regions and the cerebrospinal fluid (CSF) suggests reduced cholesterol levels, increased cholesterol levels and no changes in cholesterol levels in AD patients versus control subjects. As told by the study of Mason et al. cholesterol levels were lower in the temporal gyrus of autopsied brains of AD patients than control subjects [72]. Sparks found that cholesterol levels in the frontal cortex gray matter of AD patients were modestly but significantly higher with the APOE ϵ 4 genotype related to APOE ϵ 4 control subjects [73].

According to the study of Heverin et al. cholesterol levels were analogous in the cerebral cortex of AD and control subjects [74]. The same researcher also noted an increase in cholesterol levels in the basal ganglia of AD patients with respect to control subjects [74]. In accordance with the study of Eckert et al. cholesterol levels did not differ in hippocampal tissue of AD patients compared to control subjects [75]. Previous studies have confirmed that subjects with dementia and depression had considerably lower serum cholesterol levels than the control subjects [76]. Brain cholesterol levels of AD patients are highly variable consequence elevated total serum cholesterol levels in either mid-life or later do not have a major role in the development of AD.

Role of ApoE in the development and progression of Alzheimer's disease

ApoE is a 299 amino acid glycoprotein and the major apolipoprotein in the brain [77]. In the central nervous system (CNS), ApoE is mainly produced by astrocytes [27]. ApoE transports cholesterol to neurons via ApoE receptors, which are members of the low density lipoprotein (LDL) receptor gene family [78,79].

ApoE is polymorphic, there are three common alleles of the APOE gene: Apo ϵ 2 (Cys112, Cys158), Apo ϵ 3 (Cys112, Arg158) and Apo ϵ 4 (Arg112, Arg158) [80,81]. Apo ϵ 2 has an allele frequency of approximately 7% and Apo ϵ 3 has an allele frequency of approximately 79% [82]. There is also confirmation that the Apo ϵ 2 allele may exert a protective role in AD as stated earlier [83]. Apo ϵ 4 has an allele frequency of approximately 14% and present in at least one copy in approximately 25% of the population [56,82]. A number of studies confirmed that Apo ϵ 4 allele is the most prevalent genetic risk factor for AD [84]. Studies suggested that about 2% subjects that are homozygous for APOE ϵ 4 alleles are eight times more likely to develop AD than subjects that are homozygotes for APOE ϵ 3 [56]. In fact, APOE ϵ 4 is not a determinant of the AD its neither necessary nor sufficient to cause AD, it just increases the chance of AD [27].

Frequency	ApoE (%)		
	ϵ 2	ϵ 3	ϵ 4
General people	8.4	77.9	13.7
AD patients	3.9	59.4	36.7

Table 1: Worldwide projected human allele frequencies of ApoE [85].

Studies showed that subjects with the APOE ϵ 4 allele tend to have high serum LDL [44]. In addition, previous study recommended that a high cholesterol level is positively connected with long life of people over 85 years old and in some cases has been shown to be associated with better memory function and reduced dementia [86]. But here is also confusion, since a study showed that although APOE ϵ 4 has been found to double the odds of AD, high cholesterol can nearly triple the threat of AD [59].

Dietary fats and the risk of Alzheimer's disease

Dietary fat composition is an important factor in the neuropathology of AD [64,87]. The main classes of dietary fatty acids are saturated fatty acids (SFA), trans fatty acids (TFA), monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) [88]. Two essential fatty acids for human are α -linoleic acid (18:2, n-6) and α -linolenic acid (18:3, n-3). In addition, dietary fatty acids are also essential for the sufficient absorption of the lipid soluble vitamins (Vitamin A, D, E and K) [64].

Most of the studies based on laboratory research, animal as well as epidemiologic studies showed that consumptions of high saturated and trans fatty acid increase the chance of dementia and lower risk with the consumptions of high unsaturated fatty acid [64,89] Grimm et al. in the cell culture experiments reported that TFA increased amyloidogenic APP and decreased non-amyloidogenic APP with respect to cis forms of oleic and PUFA [90]. Further, their study found that the TFA also increased A β aggregation [90]. Oksman et al. in the study of transgenic mice found that administration of the westernized diet of 40% SFA for the period of 4 months increased the concentration of A β in the brain with respect to soy oil based diet [91].

However, another study of aged dogs found that diets high in SFA and low in MUFA increased learning faults and decreased cognitive functions [92]. But, another study of Winocur and Greenwood in transgenic mice found diets high in SFA causes learning and memory dysfunction by impairing glucose regulation resulting in reduced glucose uptake in the hippocampus [93].

Several studies recommend that intake of saturated fat increases the risk of AD or cognitive impairment and intake of monounsaturated and polyunsaturated fats has protective effects [93]. Numerous prospective dietary studies also reported similar outcomes. Morris et al. has shown that intakes of saturated fat and trans-unsaturated fat were positively associated with the risk of AD, whereas intakes of ω-6 polyunsaturated fat and monounsaturated fat were inversely associated [94]. They examined that high intake of saturated fats doubled the risk of Alzheimer's and even moderate intake of trans fat increased the risk by 2 to 3 times in Chicago [94].

The study of Luchsinger et al. in New York found a greater risk of AD for those with higher intakes of total fat and saturated fat, but no

evidence of an association with the intake of polyunsaturated fats [95]. Researchers of the Rotterdam study also found an increased risk of disease with higher intakes of total fat, saturated fat and cholesterol after 2 years of follow-up, but none of the dietary fat was associated with AD after 6 years of follow-up [40].

A number of prospective epidemiologic studies have investigated the relationship of dietary fatty acid composition to the risk of developing cognitive dysfunction [global cognitive (GC), mild cognitive impairment (MCI), mini mental state examination (MMSE)] and dementia [AD, vascular dementia (VD)] represented in Table 2.

Name of the Study	N	Follow-up (y)	SFA	TFA	MUFA	PUFA	Result
Beydoun et al. [96]	2251	6	I	-	-	D	GC
Devore et al. [97]	1486	1.8	I	I	d	-	GC
Engelhart et al. [98]	5395	6	D	D	-	-	AD
			-	-	-	-	Dementia
Eskelinen et al. [99]	1449	21	I	-	-	d	MCI
			I	-	-	-	GC
Heude et al. [100]	246	4.4	I	-	-	I	MMSE
Kalmijn et al. [40]	5395	2	-	-	-	-	AD
			i	-	-	-	VD
Laitinen et al. [101]	1449	21	i	-	d	d	AD
Luchsinger et al. [95]	980	4	i	-	-	-	AD
Morris et al. [94]	815	3.9	I	I	d	d	AD
Morris et al. [102]	2560	6	I	I	d	d	GC
Naqvi et al. [103]	482	3	-	-	D	-	GC
Okereke et al. [104]	6183	9	I	-	D	-	GC
Roberts et al. [105]	937	3.7	-	-	-	d	MCI
Ronnemaa et al. [106]	838	35	D	-	-	I	AD
Samieri et al. [107]	1214	4	-	-	-	-	GC
Solfrizzi et al. [108]	704	8.5	-	-	d	d	MMSE
Vercambre et al. [109]	2551	8.9	-	-	d	d	GC

Table 2: Prospective epidemiologic studies of dietary fats and the risk of cognitive dysfunction and dementia [100-116]. [Where, I=Statistically significant increased risk; D=Statistically significant decreased risk; i=Marginally statistically significant increased risk; d=Marginally statistically significant decreased risk].

Ketogenic diets as a therapeutic target for Alzheimer's disease

KD is a high-fat, medium-protein and low-carbohydrate diet [110]. The KD is so-termed, as maintenance of this diet induces and sustains a ketosis state in the body [111]. The ability of KB to increase

mitochondrial efficiency and supplement of glucose makes them attractive compounds to treat AD and other neurological disorders [112]. The KD has demonstrated potential in treating several neurological disorders given in Table 3.

Name of the Study	Species	Disease Model	Result
Dardzinsk et al. [113]	Rats	Hypoxia ischemia	Neuroprotection
Imamura et al. [114]	Cell culture	Parkinson' disease	Increased cell survival
Kashiway et al. [115]	Cell culture	Alzheimer's disease	Increased cell survival
Klepper et al. [116]	Human	GLUT1 haploinsufficiency	Decrease seizure frequency
Maalouf et al. [117]	Cell culture	Glutamate toxicity	Increased mitochondrial efficiency
Massieu et al. [118]	Rat cell culture	Glutamate toxicity	Neuroprotection
Masuda et al. [119]	Cell culture	Hypoxia	Increased cell survival
Mejia-Toiber et al. [120]	Rats	Glutamate toxicity	Neuroprotection and reduced lipid peroxidation
Noh et al. [121]	Mice	Kainic acid-induced seizures	Increased cell survival
Noh et al. [122]	Cell culture	Glutamate toxicity	Increased cell survival
Prins et al. [123]	Rats	Traumatic brain injury	Reduced contusion volume
Prins et al. [124]	Rats	Traumatic brain injury	Restored ATP levels after controlled cortical impact
Suzuki et al. [125]	Mice	Hypoxia	Maintained ATP and low lactate
Suzuki et al. [126]	Mice	Ischemia	Reduced cerebral infarct area
Tieu et al. [127]	Mice	Parkinson's disease	Improved neuronal survival, improved mitochondrial efficiency
Vanitallie et al. [128]	Human	Parkinson's disease	Improved motor function
Van der Auwera et al. [129]	Mice	Alzheimer's disease	Reduced A β levels
Zhao et al. [130]	Mice	Amyotrophic lateral sclerosis	Increased motor neuron counts

Table 3: Neuroprotective effect of ketogenic diets against various neurological disease models [113-130].

In the study of effects of β -hydroxybutyrate (β -HB) on cognition in memory-impaired adults by Reger et al. reported that ketone levels were positively correlated with memory performance [131]. In this study, 20 subjects with AD and or MCI consumed a drink containing emulsified medium chain triglycerides (MCT) or placebo on separate days. When cognitive tests were performed after 90 min, marked ($P=0.007$) increases in levels of the ketone body, β -HB was observed. APOE genotype moderated β -HB rises. It was found that subjects with Apo ϵ 4 (ϵ 4+), β -HB levels gradually rise between the 90 and 120 min blood draws in the treatment condition, but for subjects without Apo ϵ 4 (ϵ 4-), β -HB levels remained constant ($P<0.009$). Contrariwise on cognitive testing, MCT treatment aided performance on the AD Assessment Scale-Cognitive Subscale (ADAS-cog) for ϵ 4- subjects, but not for ϵ 4+ subjects ($P=0.04$). In all subjects, higher ketone levels corresponded with greater memory improvements (paragraph recall) with MCT treatment relative to placebo ($P=0.02$) [131].

These preliminary, short-term findings were followed up later by Henderson et al. among 152 subjects with mild to moderate AD [132]. In this study a ketogenic compound was administered to subjects for 90 days and cognitive performance was determined by using ADAS-Cog, MMSE and AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) [132]. In this study an oral ketogenic compound was compared with respect to placebo in several subject groups, including: intention-to-treat (ITT), per protocol (PP) and

dosage compliant (DC) groups. In each of the subject groups, a significant difference was found between ketogenic compound and placebo in mean change from baseline in ADAS-Cog score among subjects who did not carry the Apo ϵ 4 allele on 45th and 90th day. In the ITT subjects, ϵ 4- subjects (N=55) administered ketogenic compound had a significant of 4.77 point difference in mean change from baseline in ADAS-Cog scores at 45th day ($P=0.0005$) and a 3.36 point difference at 90th day ($P=0.0148$) compared to placebo. In the PP subjects, ϵ 4- subjects receiving ketogenic compound (N=37) differed from placebo by 5.73 points at 45th day ($P=0.0027$) and by 4.39 points on 90th day ($P=0.0143$). In the DC subjects, ϵ 4- subjects receiving ketogenic compound differed from placebo by 6.26 points at 45th day ($P=0.0011$, N=38) and 5.33 points on 90th day ($P=0.0063$, N=35). Furthermore, it was found that after 2 h of administration of ketogenic compound, noticeable rises in a serum ketone body especially β -HB was reported with respect to placebo [132].

Lane-Donovan et al. investigate the effect of diet on ApoE levels by feeding wildtype, ApoE3, and ApoE4 targeted replacement (TR) mice with chow, high-fat, or ketogenic diets [133]. This study found that a high-fat diet reduced hippocampal ApoE levels in mice expressing human ApoE3, but not ApoE4 or murine ApoE, and this effect was not observed after a similar amount of time on a ketogenic diet. Moreover, while a high-fat diet increased steady state plasma ApoE levels in all genotypes, a KD only increased plasma ApoE levels in human ApoE4

TR mice. The KD had no effect on hippocampal ApoE. Together, these results suggest that dietary composition alters ApoE protein levels in an isoform-specific manner. Researchers suggest that the use of dietary interventions to slow the progression AD should take ApoE genotype into consideration [133].

These auspicious primary outcomes of ketogenic compounds presented optimism that dietary interferences might likewise benefit brain health. Krikorian et al. examined the effect of carbohydrate diet on memory of 23 older subjects with MCI by using clinical dementia rating (CDR), trail making test (TMT) part B, verbal paired associate learning test (V-PAL) and geriatric depression scale (GDS) [134]. This study found improved verbal memory performance in the low carbohydrate subjects ($P=0.01$) compared to those on a high-carbohydrate diet after six-week intervention period. However, for low carbohydrate subjects, reductions in weight ($P<0.0001$), waist circumference ($P<0.0001$), fasting glucose ($P=0.009$) and fasting insulin ($P=0.005$) were also observed. Ketone levels were positively correlated with memory performance ($P=0.04$). These findings indicate that very low carbohydrate consumption, even in the short-term, can improve memory function in older adults with an increased risk for Alzheimer's. The researcher conclude, although this effect may be attributable in part to correction of hyperinsulinemia, other mechanisms associated with ketosis such as reduced inflammation and enhanced energy metabolism also may have contributed to improved neurocognitive function [134].

The therapeutic potentiality of the ketosis hasn't been strictly tested in a formal clinical trial, but current a case study of Newport et al. delivers an astonishing therapeutic target for controlling AD [135]. In this study a 63 year old man with younger-onset, sporadic AD for 12 years began consuming 35 ml of coconut oil (CO) once daily [CO contains ~15% ketogenic medium-chain fatty acids (MCFA)]. After several months, medium-chain triglyceride (MCTG) was added and increased gradually to a 4:3 mixture with CO, eventually reaching 165 ml/day divided into 3 to 4 servings. Use of the MCTG/CO mixtures as dietary supplements was associated with rapid improvement of score of MMSE from 12 to 20, after 2.5 months. Later that additional gradual improvement occurred in gait, social participation, word finding and recall of recent events. Thus, during MCFG treatment for twenty months, the ADAS-Cog score of the patient rose to 6 points and activities of daily living (ADLs) rose 14 points, followed by stabilization. The magnetic resonance imaging (MRI) of the patient showed no further brain atrophy. After that, ketone monoester (KME) was incorporated in the diet of the patient. As a result, the living functions, behavior as well as cognitive ability of the patient were improved. After six to eight weeks of taking 28.7 g of the KME thrice daily, the patient began to exhibit improvement in memory retrieval, spontaneously discussing events that occurred up to a week earlier. In addition, plasma β -HB levels were measured before and during KME treatment to assess KME-plasma β -HB dose-response relationships. The only noteworthy changes were in certain plasma lipids. Over 20 months, total cholesterol fell from a pre-KME mean ($n=2$) of 244 to 163 mg/dL. HDL cholesterol fell from 85 to 68 mg/dL and LDL cholesterol from 145 to 81 mg/dL. Notably, this man carried the Apo ϵ 4 gene, thus researchers resolved that ketosis does appear to be highly beneficial for Apo ϵ 4 carriers, even if prior studies indicate it's even *more* helpful for those without this risk factor [135].

Conclusion

Still now Alzheimer's is incurable, but the current treatment strategy can improve the quality of life of the patients by slowing the worsening of the symptoms of dementia. For the efficacious treatment of AD if ketosis is to become affirmed, additional investigation is essential to ascertain the proper mode of administration, since high-fat diets, MCFA, MCT supplements or ketogenic compounds may be discretely efficient. In addition, patient compliance could also represent challenges owing to administering strict diet or supplements. However, it is very inevitable to mark out the minimum and maximum effective dose that will aid to fix the treatment regimen. In spite of these existing questions, the therapeutic potentiality of ketogenic diet suggests a powerful weapon in the fight against the development and progression of AD.

Author's Contribution

This work was carried out in collaboration between all authors. Author MSU designed the study, wrote the protocol, managed the analyses of the study and prepared the draft of the manuscript. Authors AAM, MAI, MTK, RKR and MMB managed the literature searches under supervision of author MSU. Author AH reviewed the scientific contents of the manuscript. All the authors read and approved the final manuscript.

Acknowledgement

The authors wish to thank the anonymous reviewer(s)/editor(s) of this article for their constructive reviews. The authors are also grateful to the Department of Pharmacy, Southeast University, Dhaka, Bangladesh.

Competing Interests

The authors proclaim that they have no competing interests.

References

1. Uddin MS, Asaduzzaman M, Mamun AA, Iqbal MA, Wahid F, et al. (2016) Neuroprotective activity of *Asparagus racemosus* Linn. against ethanol-induced cognitive impairment and oxidative stress in rats brain: Auspicious for controlling the risk of Alzheimer's disease. *J Alzheimers Dis Parkinsonism* 6: 245.
2. Uddin MS, Nasrullah M, Hossain MS, Rahman MM, Sarwar MS, et al. (2016) Evaluation of nootropic activity of *Persicaria flaccida* on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: Implication for the management of Alzheimer's disease. *Ame J Psychi Neurosci* 4: 26-27.
3. Nordberg A (2008) Amyloid plaque imaging *in vivo*: Current achievement and future prospects. *Eur J Nucl Med Mol Imaging* 35 Suppl 1: S46-50.
4. Butterfield DA, Boyd-Kimball D (2004) Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. *Brain Pathol* 14: 426-432.
5. Uddin MS, Mamun AA, Hossain MS, Akter F, Iqbal MA, et al. (2016) Exploring the effect of *Phyllanthus emblica* L. on cognitive performance, brain antioxidant markers and Acetylcholinesterase activity in rats: Promising natural gift for the mitigation of Alzheimer's disease. *Ann Neurosci* 23: 218-219.
6. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins and therapy. *Physiol Rev* 81: 741-766.
7. Uddin MS, Mamun AA, Iqbal MA, Islam A, Hossain MF, et al. (2016) Analyzing nootropic effect of *Phyllanthus reticulatus* Poir. on cognitive

- functions, brain antioxidant enzymes and acetylcholinesterase activity against aluminium-induced Alzheimer's model in rats: Applicable for controlling the risk factors of Alzheimer's disease. *Adv Alzheimer's Dis* 5: 87-88.
8. Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Prog Neurobiol* 70: 1-32.
 9. Nunan J, Small DH (2000) Regulation of APP cleavage by alpha-, beta- and gamma-secretases. *FEBS Lett* 483: 6-10.
 10. Cole SL, Vassar R (2007) The Alzheimer's disease beta-secretase enzyme, BACE1. *Mol Neurodegener* 2: 22.
 11. Harkany T, Abraham I, Timmerman W, Laskay G, Tóth B, et al. (2000) beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. *Eur J Neurosci* 12: 2735-2745.
 12. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. *Trends Cell Biol* 8: 447-453.
 13. Cheng Y, Judd TC, Bartberger MD, Brown J, Chen K, et al. (2011) From fragment screening to *in vivo* efficacy: Optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). *J Med Chem* 54: 5836-5857.
 14. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM (2007) {Gamma}-secretase substrate concentration modulates the $\text{A}\beta_{42}/\text{A}\beta_{40}$ ratio: Implications for Alzheimer disease. *J Biol Chem* 282: 23639-44.
 15. Ridge PG, Ebbert MT, Kauwe JS (2013) Genetics of Alzheimer's disease. *Biomed Res Int* 2013: 254954.
 16. Pulawski W, Ghoshdastider U, Andrisano V, Filipek S (2012) Ubiquitous amyloids. *Appl Biochem Biotechnol* 166: 1626-1643.
 17. Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, et al. (2015) Amyloid-beta: A crucial factor in Alzheimer's disease. *Med Princ Pract* 24: 1-10.
 18. Alzheimer's Disease Education and Referral Center. Alzheimer's disease Genetics.
 19. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. *Ann N Y Acad Sci* 1144: 97-112.
 20. Revett TJ, Baker GB, Jhamandas J, Kar S (2013) Glutamate system, amyloid β peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. *J Psychiatry Neurosci* 38: 6-23.
 21. Weggen S, Behr D (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. *Alzheimers Res Ther* 4: 9.
 22. Hasan T (2016) Exploring the intertwined roles of APOE and ABC genes in the cognitive decline of Alzheimers. *Int J Res Sci* 2: 1-3.
 23. Goedert M, Klug A, Crowther RA (2006) Tau protein, the paired helical filament and Alzheimer's disease. *J Alzheimers Dis* 9: 195-207.
 24. Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. *Cold Spring Harb Perspect Med* 2: a006239.
 25. Liu Y, Yu JT, Wang HE, Han PR, Tan CC, et al. (2015) APOE genotype and neuroimaging markers of Alzheimer's disease: Systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 86: 127-134.
 26. Huang W, Qiu C, von Strauss R, Winblad B, Fratiglioni L (2004) APOE genotype, family history of dementia and Alzheimer disease risk: A 6 year follow-up study. *Arch Neurol* 61: 1930-1934.
 27. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat Rev Neurol* 9: 106-118.
 28. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proc Natl Acad Sci U S A* 103: 5644-5651.
 29. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. *Lancet* 368: 387-403.
 30. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. (1999) APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The cache county study. *Neurology* 53: 321-331.
 31. van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes LM, et al. (1994) Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. *Nat Genet* 7: 74-78.
 32. Luchsinger JA, Mayeux R (2004) Dietary factors and Alzheimer's disease. *Lancet Neurol* 3: 579-587.
 33. Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, et al. (2011) Diet and Alzheimer's disease risk factors or prevention: The current evidence. *Expert Rev Neurother* 11: 677-708.
 34. Refolo LM, Malester B, La Franco J, Bryant-Thomas T, Wang R, Tint GS, et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiol Dis* 7:321-331.
 35. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *FASEB J* 18: 902-904.
 36. Levin-Allerhand JA, Lominska CE, Smith JD (2002) Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. *J Nutr Health Aging* 6: 315-319.
 37. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. *Neuroreport* 13: 455-459.
 38. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, et al. (2004) APP intracellular domain is increased and soluble A beta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. *Neurobiol Dis* 16: 124-132.
 39. Veselic S (2015) What's the connection between saturated fat and dementia?
 40. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, et al. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. *Ann Neurol* 42: 776-782.
 41. Giem P, Beeson WL, Fraser GE (1993) The incidence of dementia and intake of animal products: Preliminary findings from the Adventist Health Study. *Neuroepidemiology* 12: 28-36.
 42. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA (2006) Mediterranean diet and risk for Alzheimer's disease. *Ann Neurol* 59: 912-921.
 43. Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, et al. (2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. *Neurology* 65: 1409-1414.
 44. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, et al. (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele and Alzheimer's disease. *Neuroepidemiology* 17: 14-20.
 45. Satyanarayana U, Chakrapani U (2006) *Biochemistry*. (3rd edn). Kolkata: Books and Allied (P) Ltd.
 46. Gasior M, Rogawski MA, Hartman AL (2006) Neuroprotective and disease-modifying effects of the ketogenic diet. *Behav Pharmacol* 17: 431-439.
 47. Appelberg KS, Hovda DA, Prins ML (2009) The effects of a ketogenic diet on behavioral outcome after controlled cortical impact injury in the juvenile and adult rat. *J Neurotrauma* 26: 497-506.
 48. Xu K, Sun X, Eroku BO, Tsipis CP, Puchowicz MA, et al. (2010) Diet-induced ketosis improves cognitive performance in aged rats. *Adv Exp Med Biol* 662: 71-75.
 49. Henderson ST (2008) Ketone bodies as a therapeutic for Alzheimer's disease. *Neurotherapeutics* 5: 470-480.
 50. Sullivan PG, Rippey NA, Dorenbos K, Concepcion RC, Agarwal AK, et al. (2004) The ketogenic diet increases mitochondrial uncoupling protein levels and activity. *Ann Neurol* 55: 576-580.
 51. Chang CY, Ke DS, Chen JY (2009) Essential fatty acids and human brain. *Acta Neurol Taiwan* 18: 231-241.
 52. Nys M, Debruyne I (2011) Lipids and Brain 2: A symposium on lipids and brain health. *Inform* 22: 397.
 53. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. *Curr Opin Lipidol* 12: 105-112.

54. Petrov AM, Kasimov MR, Zefirov AL (2016) Brain cholesterol metabolism and its defects: Linkage to neurodegenerative diseases and synaptic dysfunction. *Acta Naturae* 8: 58-73.
55. Pfrieger FW (2003) Role of cholesterol in synapse formation and function. *Biochim Biophys Acta* 1610: 271-280.
56. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: The cholesterol connection. *Nat Neurosci* 6: 345-351.
57. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, et al. (2003) Apolipoprotein E epsilon4 allele, AD pathology and the clinical expression of Alzheimer's disease. *Neurology* 60: 246-252.
58. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, et al. (2011) Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *J Epidemiol Community Health* 65: 949-957.
59. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. *Ann Intern Med* 137: 149-155.
60. Mainous AG, Eschenbach SL, Wells BJ, Everett CJ, Gill JM (2005) Cholesterol, transferrin saturation and the development of dementia and Alzheimer's disease: Results from an 18 year population-based cohort. *Fam Med* 37: 36-42.
61. Reynolds CA, Gatz M, Prince JA, Berg S, Pedersen NL (2010) Serum lipid levels and cognitive change in late life. *J Am Geriatr Soc* 58: 501-509.
62. Popp J, Meichsner S, Kölsch H, Lewczuk P, Maier W, et al. (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. *Biochem Pharmacol* 86: 37-42.
63. Popp J, Lewczuk P, Kölsch H, Meichsner S, Maier W, et al. (2012) Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. *J Neurochem* 123: 310-316.
64. Morris MC, Tangney CC (2014) Dietary fat composition and dementia risk. *Neurobiol Aging* 35: S59-64.
65. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 64: 277-281.
66. Knittweis JW, McMullen WA (2000) The effect of apoE on dementia is not through atherosclerosis: The Rotterdam study. *Neurology* 54: 2356-2358.
67. Stewart R, White LR, Xue QL, Launer LJ (2007) Twenty-six-year change in total cholesterol levels and incident dementia: The Honolulu-Asia Aging Study. *Arch Neurol* 64: 103-107.
68. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: A report from the American Heart Association. *Circulation* 127: e6-e245.
69. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. *Neurology* 80: 1778-1783.
70. Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. *J Cereb Blood Flow Metab* 33: 1500-1513.
71. Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. *Biochem Pharmacol* 65: 843-856.
72. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette LG (1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. *Neurobiol Aging* 13: 413-419.
73. Sparks DL (1997) Coronary artery disease, hypertension, ApoE and cholesterol: A link to Alzheimer's disease? *Ann N Y Acad Sci* 826: 128-146.
74. Heverin M, Bogdanovic N, Lütjohann D, Bayer T, Pikuleva I, et al. (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. *J Lipid Res* 45: 186-193.
75. Eckert GP, Cairns NJ, Maras A, Gattaz WF, McEuler WE (2000) Cholesterol modulates the membrane disordering effects of b-amyloid peptides in the hippocampus: Specific changes in Alzheimer's disease. *Dement Geriatr Cogn Disord* 11: 181-186.
76. Dimopoulos N, Piperi C, Salonicioti A, Psarra V, Mitsonis C, et al. (2007) Characterization of the lipid profile in dementia and depression in the elderly. *J Geriatr Psychiatry Neurol* 20: 138-144.
77. Phillips MC (2014) Apolipoprotein E isoforms and lipoprotein metabolism. *IUBMB Life* 66: 616-623.
78. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. *Biochem Biophys Acta* 917: 148-161.
79. DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, et al. (2001) Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. *Neurochem Int* 39: 415-425.
80. Singh PP, Singh M, Mastana SS (2006) APOE distribution in world populations with new data from India and the UK. *Ann Hum Biol* 33: 279-308.
81. Ghebranion N, Ivacic L, Mallum J, Dokken C (2005) Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. *Nucleic Acids Res* 33: e149.
82. (2016) Alzgene-meta-analysis of all published ad association studies (case-control only) ApoE_E2/3/4.
83. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* 7: 180-184.
84. Sadigh-Eteghad S, Talebi M, Farhoudi M (2012) Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis. *Neurosciences (Riyadh)* 17: 321-326.
85. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al. (1997) Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta-analysis consortium. *JAMA* 278: 1349-56.
86. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, et al. (1997) Total cholesterol and risk of mortality in the oldest old. *Lancet* 350: 1119-1123.
87. Mercola (2014) Key dietary strategies to protect yourself from Alzheimer's.
88. Linscheer WG, Vergroesen AJ (1994) Lipids. In: Shils M, Olson JA, Shike M (edn), *Modern nutrition in health and disease*, Philadelphia: Lea & Febiger.
89. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1997) Polyunsaturated fatty acids, antioxidants and cognitive function in very old men. *Am J Epidemiol* 145: 33-41.
90. Grimm MO, Rothhaar TL, Grösgen S, Burg VK, Hundsdoerfer B, et al. (2012) Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). *J Nutr Biochem* 23: 1214-1223.
91. Oksman M, Iivonen H, Högges E, Amtl Z, Penke B, et al. (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. *Neurobiol Dis* 23: 563-572.
92. Snigdha S, Astarita G, Piomelli D, Cotman CW (2012) Effects of diet and behavioural enrichment on free fatty acids in the aged canine brain. *Neuroscience* 202: 326-333.
93. Winocur G, Greenwood CE (2005) Studies of the effects of high fat diets on cognitive function in a rat model. *Neurobiol Aging* 1: 46-49.
94. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, et al. (2003) Dietary fats and the risk of incident Alzheimer disease. *Arch Neurol* 60: 194-200.
95. Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric intake and the risk of Alzheimer disease. *Arch Neurol* 59: 1258-1263.
96. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR (2007) Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the

- Atherosclerosis Risk in Communities Study. *Am J Clin Nutr* 85: 1103-1111.
97. Devore EE, Stampfer MJ, Breteler MM, Rosner B, Kang JH, et al. (2009) Dietary fat intake and cognitive decline in women with type 2 diabetes. *Diabetes Care* 32: 635-640.
98. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, et al. (2002) Diet and risk of dementia: Does fat matter? The Rotterdam Study. *Neurology* 59: 1915-1921.
99. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, et al. (2008) Fat intake at midlife and cognitive impairment later in life: A population-based CAIDE study. *Int J Geriatr Psychiatry* 23: 741-747.
100. Heude B, Ducimetière P, Berr C (2003) Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. *Am J Clin Nutr* 77: 803-808.
101. Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, et al. (2006) Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. *Dement Geriatr Cogn Disord* 22: 99-107.
102. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2004) Dietary fat intake and 6 year cognitive change in an older biracial community population. *Neurology* 62: 1573-1579.
103. Naqvi AZ, Harty B, Mukamal KJ, Stoddard AM, Vitolins M, et al. (2011) Monounsaturated, trans and saturated Fatty acids and cognitive decline in women. *J Am Geriatr Soc* 59: 837-843.
104. Okereke OI, Rosner BA, Kim DH, Kang JH, Cook NR, et al. (2012) Dietary fat types and 4 year cognitive change in community-dwelling older women. *Ann Neurol* 72: 124-134.
105. Roberts RO, Roberts LA, Geda YE, Cha RH, Pankratz VS, et al. (2012) Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia. *J Alzheimers Dis* 32: 329-339.
106. Rönnemaa E, Zethelius B, Vessby B, Lannfelt L, Byberg L, et al. (2012) Serum fatty-acid composition and the risk of Alzheimer's disease: A longitudinal population-based study. *Eur J Clin Nutr* 66: 885-890.
107. Samieri C, Féart C, Letenneur L, Dartigues JF, Pérès K, et al. (2008) Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. *Am J Clin Nutr* 88: 714-721.
108. Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. (2006) Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5 year follow-up of the Italian longitudinal study on aging. *Neurobiol Aging* 27: 1694-1704.
109. Vercambre MN, Grodstein F, Kang JH (2010) Dietary fat intake in relation to cognitive change in high-risk women with cardiovascular disease or vascular factors. *Eur J Clin Nutr* 64: 1134-1140.
110. Freeman JM, Kossoff EH, Hartman AL (2007) The ketogenic diet: one decade later. *Pediatrics* 119: 535-543.
111. Hallböök T, Ji S, Maudsley S, Martin B (2012) The effects of the ketogenic diet on behavior and cognition. *Epilepsy Res* 100: 304-309.
112. Veech RL (2004) The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance and mitochondrial metabolism. *Prostaglandin, Leukotriene and Essential Fatty Acids* 70: 309-319.
113. Dardzinski BJ, Smith SL, Towfighi J, Williams GD, Vannucci RC, et al. (2000) Increased plasma beta-hydroxybutyrate, preserved cerebral energy metabolism, and amelioration of brain damage during neonatal hypoxia ischemia with dexamethasone pretreatment. *Pediatr Res* 48: 248-255.
114. Imamura K, Takeshima T, Kashiwaya Y, Nakaso K, Nakashima K (2006) D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. *J Neurosci Res* 84: 1376-1384.
115. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, et al. (2000) D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. *Proc Natl Acad Sci U S A* 97: 5440-5444.
116. Klepper J, Leiendecker B (2007) GLUT1 deficiency syndrome--2007 update. *Dev Med Child Neurol* 49: 707-716.
117. Maalouf M, Sullivan PG, Davis L, Kim DY, Rho JM (2007) Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. *Neurosci* 145: 256-264.
118. Massieu L, Haces ML, Montiel T, Hernandez-Fonseca K (2003) Acetoacetate protects hippocampal neurons against glutamate-mediated neuronal damage during glycolysis inhibition. *Neurosci* 120: 365-378.
119. Masuda R, Monahan JW, Kashiwaya Y (2005) D-beta-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures. *J Neurosci Res* 80: 501-509.
120. Mejia-Toiber J, Montiel T, Massieu L (2006) D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition *in vivo*. *Neurochem Res* 31: 1399-1408.
121. Noh HS, Kim YS, Lee HP, Chung KM, Kim DW, et al. (2003) The protective effect of a ketogenic diet on kainic acid-induced hippocampal cell death in the male ICR mice. *Epilepsy Res* 53: 119-128.
122. Noh HS, Hah YS, Nilufar R, Han J, Bong JH, et al. (2006) Acetoacetate protects neuronal cells from oxidative glutamate toxicity. *J Neurosci Res* 83: 702-709.
123. Prins ML, Fujima LS, Hovda DA (2005) Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury. *J Neurosci Res* 82: 413-420.
124. Prins ML, Lee SM, Fujima LS, Hovda DA (2004) Increased cerebral uptake and oxidation of exogenous betaHB improves ATP following traumatic brain injury in adult rats. *J Neurochem* 90: 666-672.
125. Suzuki M, Suzuki M, Sato K, Dohi S, Sato T, et al. (2001) Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. *Jpn J Pharmacol* 87: 143-150.
126. Suzuki M, Suzuki M, Kitamura Y, et al. (2002) Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. *Jpn J Pharmacol* 89: 36-43.
127. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, et al. (2003) D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. *J Clin Invest* 112: 892-901.
128. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, et al. (2005) Treatment of Parkinson disease with diet-induced hyperketonemia: A feasibility study. *Neurology* 64: 728-730.
129. Van der Auwera I, Wera S, Van Leuven F, Henderson ST (2005) A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. *Nutr Metab (Lond)* 2: 28.
130. Zhao Z, Lange DJ, Voustantiounk A, MacGrogan D, Ho L, et al. (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. *BMC Neurosci* 7: 29.
131. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, et al. (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. *Neurobiol Aging* 25: 311-314.
132. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, et al. (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab* 6: 31.
133. Lane-Donovan C, Herz J (2016) High-fat diet changes hippocampal apolipoprotein E (ApoE) in a genotype- and carbohydrate-dependent manner in mice. *PLoS One* 11: e0148099.
134. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, et al. (2012) Dietary ketosis enhances memory in mild cognitive impairment. *Neurobiol Aging* 33: 425.
135. Newport MT, VanItallie TB, Kashiwaya Y, King MT, Veech RL (2015) A new way to produce hyperketonemia: Use of ketone ester in a case of Alzheimer's disease. *Alzheimers Dement* 11: 99-103.